The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.

Blood
Kieron DunleavyWyndham H Wilson

Abstract

This is a phase 2 study to assess the role of tumor histogenesis (subtype), fluorodeoxyglucose positron emission tomography (FDG-PET), and short-course etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with dose-dense rituximab (SC-EPOCH-RR) in newly diagnosed HIV-associated CD20(+) diffuse large B-cell lymphoma. Patients received a minimum of 3 and a maximum of 6 cycles with 1 cycle beyond stable radiographic and FDG-PET scans. Overall, 79% of patients received 3 cycles. Combination antiretroviral therapy was suspended before and resumed after therapy. Thirty-three enrolled patients had a median age of 42 years (range, 9-61 years), and 76% had a high-intermediate or high age-adjusted international prognostic index. At 5 years median follow-up, progression-free and overall survival were 84% and 68%, respectively. There were no treatment-related deaths or new opportunistic infections during treatment, and patients had sustained CD4 cell count recovery and HIV viral control after treatment. FDG-PET after 2 cycles had an excellent negative but poor positive predictive value. Tumor histogenesis was the only characteristic associated with lymphoma-specific outcome with 95% of germinal center B-cell (GCB) versus 4...Continue Reading

References

Oct 23, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D G MaloneyR Levy
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L RatnerUNKNOWN AIDS Malignancy Consortium
Dec 14, 2001·Biochemical and Biophysical Research Communications·D ThéardJ M Darbon
Jun 21, 2002·The New England Journal of Medicine·Andreas RosenwaldUNKNOWN Lymphoma/Leukemia Molecular Profiling Project
Sep 27, 2003·Lancet·Alexander M ScharkoC David Pauza
Aug 24, 2005·British Journal of Haematology·Antonino Carbone, Annunziata Gloghini
Mar 24, 2006·Blood·Kieron DunleavyLawrence D Kaplan
Dec 1, 2006·The New England Journal of Medicine·UNKNOWN Strategies for Management of Antiretroviral Therapy (SMART) Study GroupC Rappoport
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malik E JuweidUNKNOWN Imaging Subcommittee of International Harmonization Project in Lymphoma
Mar 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daphne de JongUNKNOWN Lunenburg Lymphoma Biomarker Consortium
Mar 8, 2008·Science·Georg LenzLouis M Staudt
Apr 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wyndham H WilsonJohn E Janik
Nov 29, 2008·The New England Journal of Medicine·G LenzUNKNOWN Lymphoma/Leukemia Molecular Profiling Project
Dec 17, 2008·Critical Reviews in Oncology/hematology·Nicolas MounierJean-Philippe Spano
Dec 25, 2008·Current Opinion in Oncology·Alexandra M Levine
Sep 16, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amy ChadburnEthel Cesarman

❮ Previous
Next ❯

Citations

Apr 14, 2011·JAMA : the Journal of the American Medical Association·Meredith S ShielsEric A Engels
Jul 28, 2011·Current Oncology Reports·Juan Carlos Ramos, Izidore S Lossos
Nov 15, 2013·The New England Journal of Medicine·Kieron DunleavyWyndham H Wilson
Sep 10, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Edgar P Simard, Eric A Engels
Jul 31, 2013·Journal of the National Cancer Institute·Satish GopalKristy L Richards
Jul 31, 2013·Journal of the National Cancer Institute·Kieron Dunleavy, Wyndham H Wilson
Aug 5, 2010·Current Opinion in Oncology·Ariela Noy
Dec 10, 2013·Hematology·Richard F Little, Kieron Dunleavy
Dec 10, 2013·Hematology·Wyndham H Wilson
Nov 22, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexandra M LevineAnil Tulpule
May 19, 2012·Regenerative Medicine·Ye-Rang YunIvan Wall
Mar 5, 2013·Archives of Pathology & Laboratory Medicine·Amy ChadburnAmy A Lo
Jan 10, 2014·AIDS·Paul G RubinsteinAndrew Zloza
Mar 13, 2014·Nature Reviews. Clinical Oncology·Antonino CarboneSilvia Franceschi
Sep 11, 2013·North American Journal of Medical Sciences·Nagesh Tatero SirsathGovind Babu Kanaka Setty
Jan 25, 2012·Advances in Hematology·Caron A Jacobson, Jeremy S Abramson
May 10, 2012·Advances in Hematology·Adam M PetrichSamir Parekh
Oct 14, 2011·Leukemia & Lymphoma·Brian T Hill, John Sweetenham
Mar 30, 2013·Seminars in Diagnostic Pathology·Amy Chadburn
Jun 9, 2012·Mayo Clinic Proceedings·Stephen M Ansell, James O Armitage
Mar 14, 2012·Best Practice & Research. Clinical Haematology·Lawrence D Kaplan
Mar 5, 2016·Surgical Pathology Clinics·Lawrence K Low, Joo Y Song
Aug 29, 2012·British Journal of Haematology·Andrés J M FerreriAlessandro Re
Dec 15, 2015·Expert Review of Hematology·Chia-Ching J Wang, Lawrence D Kaplan
Jan 8, 2013·Clinical Lymphoma, Myeloma & Leukemia·Kenneth RuthJeanny B Aragon-Ching
Dec 10, 2014·Clinical Lymphoma, Myeloma & Leukemia·Adan Rios
Apr 7, 2015·Irish Journal of Medical Science·L SmythE Vandenberghe
Mar 26, 2015·Seminars in Hematology·Emmanuel Bachy, Gilles Salles
Feb 18, 2012·Blood·Kieron Dunleavy, Wyndham H Wilson
Apr 17, 2010·Blood·Alexandra M Levine

❮ Previous
Next ❯

Related Concepts

Related Feeds

B cell Activation

B cell activation is initiated by the ligation of the B cell receptor with antigen and ultimately results in the production of protective antibodies against potentially pathogenic invaders. Here is the latest research.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.